Saladax Biomedical has signed a distribution contract with INyDIA Labs for My5-FU, a test that measures levels of 5-fluorouracil (5-FU), in the blood of cancer patients, in Spain and Protugal.

INyDIA will provide My5-FU test kits to laboratories, enabling oncologists to individualize 5-FU dosing to optimize therapeutic efficacy and reduce toxicity for their patients.

My5-FU measures levels of 5-fluorouracil (5-FU), a chemotherapy drug used in conjunction with other drugs in first-line therapy for colorectal cancer and other solid tumors.

Saladax Sr VP and chief marketing officer Adrienne Choma said the collaboration with INyDIA will allow the company to provide cancer patients in Spain and Portugal more personalized treatment.